Transcriptional regulation of arteriovenous differentiation

动静脉分化的转录调控

• 批准号: 9376461
• 负责人: William Tswenching Pu
• 金额: $ 52.34万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9376461
• 关键词: Affect; Affinity; Alleles; Arteries; Arteriovenous malformation; Atherosclerosis; Binding; Bioinformatics; Biological Assay; Blood; Blood Vessels; Blood flow; Calcified; Cardiovascular system; Cell Line; Cells; Cerebral Arteriovenous Malformations; Childhood; Childhood stroke; Chromatin; Code; Data; Data Set; Databases; Disease; EP300 gene; Embryo; Endothelial Cells; Enhancers; Family; Gene Expression; Genes; Genetic; Genetic Transcription; Genetically Engineered Mouse; Genomics; Goals; Human; Inflammation; Informatics; Knowledge; Link; Location; Maintenance; Malignant Neoplasms; Maps; Measures; Mediator of activation protein; Methods; Molecular; Molecular Profiling; Mus; Mutagenesis; Myocardial Ischemia; Nature; Nuclear Receptors; Orphan; Pathogenesis; Pathway interactions; Pluripotent Stem Cells; Predisposition; Process; Regulation; Regulatory Element; Signal Transduction; Specific qualifier value; Specificity; Stroke; Structure; Techniques; Testing; Tissues; Transcriptional Regulation; Transgenic Organisms; VEGFA gene; Validation; Vasculitis; Veins; Venous; angiogenesis; apoAI regulatory protein-1; biochip; calcification; chicken ovalbumin upstream promoter-transcription factor; embryo cell; experimental study; gamma secretase; genome-wide; high throughput screening; human disease; improved; in vivo; induced pluripotent stem cell; inhibitor/antagonist; innovation; insight; malformation; mouse model; notch protein; novel; novel strategies; pediatric patients; precise genome editing; programs; transcription factor

Project Summary/Abstract Endothelial cells (ECs) that line the blood circulatory system belong to the arterial and venous lineages. Ar- terial and venous ECs intrinsically differ in their susceptibility to inflammation, atherosclerosis, and calcification. Moreover, disruption of genetic programs that maintain AV differences in mouse models causes arteriovenous malformations (AVMs), the leading cause of pediatric strokes. Thus understanding the genetic mechanisms that specify and maintain AV differences is critical to better understand the pathogenesis of a range of human disorders. Specification of arterial and venous lineages occurs prior to the establishment of blood flow, sug- gesting that AV differences are primarily under genetic control. Despite extensive efforts, our understanding of the molecular mechanisms that establish and maintain arterial and venous identity remains incomplete. Notch signaling has been identified as being critical for arterial differentiation, and the transcription factor COUP-TFII has been identified as being critical for venous differentiation, at least in part by antagonizing Notch signaling. In depth study of 4 transcriptional enhancers with artery selective activity has yielded anecdotal information on some features required for their artery-selective activity. However, systematic knowledge of principles that de- termine arterial or venous specific expression is lacking. In large part, this is due to the low throughput nature of the techniques that have been employed to study this problem. We have developed two unique, high throughput approaches that will surmount this barrier and yield syste- matic information about the mechanisms that are employed to yield artery or vein selective activity. First, we developed a method for high affinity, tissue-specific identification of active enhancers marked by p300, and of regulatory elements bound by the Notch target RBPJ. Second, we have developed a method for high through- put (on the order of hundreds of thousands in one experiment) testing of candidate enhancers within an inte- grated genomic context. In this proposal we apply these advances to systematically investigate arteriovenous differentiation and the mechanisms by which it is regulated by Notch signaling. In Aim 1, we test the hypothesis that identifiable transcriptional codes drive artery and vein specific transcriptional enhancer activity. We will use p300 binding in ECs to identify candidate enhancers, and then test the enhancers in parallel for artery or vein selective activity. Bioinformatic analyses of this database of enhancers with selective activity will identify the candidate transcriptional lexicon. These predictions will be tested by followup dense mutagenesis of selected enhancers, with further validation in transgenic embryo assays. In Aim 2, we focus on the mechanisms by which Notch signaling modulates RBPJ activity. We test the hy- pothesis that RBPJ regulates AV differentiation through multiple distinct Notch-dependent and -independent mechanisms. This aim hinges upon our unique ability to efficiently map RPBJ chromatin occupancy in vivo in ECs. By mapping RBPJ and p300 under Notch activated and Notch suppressed conditions in developing em- bryos, we will define the effects of Notch intracellular domain on RBPJ location and activity. Combining these data with the artery and vein selective enhancers found in Aim 1 will define artery or vein selective enhancers with Notch/RBPJ-dependent and -independent activity. This proposal is technically innovative in the novel genome-wide mapping and high throughput enhancer testing approaches. The conceptual innovation is the new understanding of artery or vein selective transcrip- tional regulation and of Notch signaling that will arise from application of these novel approaches. This proposal is significant because it will advance our understanding of angiogenesis by filling in critical gaps in our understanding of how arteriovenous differences are specified and maintained. This basic knowl- edge is relevant to diverse classes of human disease such as cancer, atherosclerosis, and inflammation.

项目总结/文摘